Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease

• Published in: Oncotarget Vol. 8; no. 62; pp. 104706 - 104716
• Main Authors: Jimenez, Amanda, Pegueroles, Jordi, Carmona-Iragui, María, Vilaplana, Eduard, Montal, Victor, Alcolea, Daniel, Videla, Laura, Illán-Gala, Ignacio, Pané, Adriana, Casajoana, Anna, Belbin, Olivia, Clarimón, Jordi, Moizé, Violeta, Vidal, Josep, Lleó, Alberto, Fortea, Juan, Blesa, Rafael
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 01.12.2017
• Subjects: Research Paper: Gerotarget (Focus on Aging); weight loss; magnetic resonance imaging; Gerotarget; cerebrospinal fluid Alzheimer’s disease biomarkers; pre-clinical Alzheimer’s disease; PET amyloid
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.22218

Weight loss has been proposed as a sign of pre-clinical Alzheimer Disease (AD). To test this hypothesis, we have evaluated the association between longitudinal changes in weight trajectories, cognitive performance, AD biomarker profiles and brain structure in 363 healthy controls from the Alzheimer´s Disease Neuroimaging Initiative (mean follow-up 50.5±30.5 months). Subjects were classified according to body weight trajectory into a weight loss group (WLG; relative weight loss ≥ 5%) and a non-weight loss group (non-WLG; relative weight loss < 5%). Linear mixed effects models were used to estimate the effect of body weight changes on ADAS-Cognitive score across time. Baseline CSF tau/AΔ ratio and AV45 PET uptake were compared between WLG and non-WLG by analysis of covariance. Atrophy maps were compared between groups at baseline and longitudinally at a 2-year follow-up using Freesurfer. WLG showed increased baseline levels of cerebrospinal fluid tau/AΔ ratio, increased PET amyloid uptake and diminished cortical thickness at baseline. WLG also showed faster cognitive decline and faster longitudinal atrophy. Our data support weight loss as a non-cognitive manifestation of pre-clinical AD.